[Cyclophosphamide in idiopathic nephrotic syndrome: Outcome and outlook].
CONCLUSION: The results presented in this study suggest the use of oral cyclophosphamide for short period remain second line effective therapy. Further well-designed trials are required to evaluate the efficacy of other steroid-sparing agents.
PMID: 29631702 [PubMed - in process]
Source: Nephrologie and Therapeutique - Category: Urology & Nephrology Authors: Berkane M, Adarmouch L, Amine M, Bourrahouat A, Ait Sab I, Sbihi M Tags: Nephrol Ther Source Type: research